Press Release Apr 29 2025
Filed with NSE · · 3 pages · English
Summary by 6ix AI
Morepen Laboratories Limited has announced the launch of Resmetirom, a new drug for fatty liver disease, following clearance from the CDSCO for bioequivalence studies. This development positions Morepen as one of the first Indian companies to enter this therapeutic area, aiming to serve both domestic and international markets. The company emphasizes its integrated capabilities and regulatory strength as key advantages in bringing this innovation to market. The press release serves to inform stakeholders about this significant advancement in Morepen's product offerings.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Morepen Laboratories Limited on 6ix
Earlier from Morepen Laboratories
- Press Release Apr 11 2025
- Press Release Apr 01 2025
- Press Release Mar 17 2025
- Press Release Jan 28 2025
- Press Release Dec 10 2024
Later from Morepen Laboratories
- Morepen Laboratories Limited Press Release May 01 2025
- Morepen Laboratories Limited Press Release May 13 2025
- Press Release (Revised) May 13 2025
- Morepen Laboratories Limited Press Release Feb 23 2026
- Press Release Apr 17 2026
Follow Morepen Laboratories into a list and get an email when it puts out news.
Follow Morepen Laboratories